Neuro & cognitive
N-Acetyl Semax Amidate
Also called NA-Semax-Amidate, N-acetyl Semax, Ac-Semax-NH2, Ac-MEHFPGP-NH2
N-Acetyl Semax Amidate is a chemically capped version of Semax, a short peptide registered as a nasal drug in Russia. It is sold online as a 'stronger' or 'longer-lasting' Semax, but we found no published study that tested this exact form in animals or people. Almost everything said about it is borrowed from research on plain Semax.
New · under editorial review. Added October 30, 2026 by our automated research, with every claim sourced. A person has not checked this page yet; treat it with extra care. How we research
Overview
N-Acetyl Semax Amidate is a chemically capped version of Semax, a short peptide registered as a nasal drug in Russia. It is sold online as a 'stronger' or 'longer-lasting' Semax, but we found no published study that tested this exact form in animals or people. Almost everything said about it is borrowed from research on plain Semax.
How it works
Unknown for this form. Semax itself is thought, from mostly animal and cell work, to have several brain effects 2. FDA's review notes that Semax is broken down quickly in rat blood and brain tissue, with breakdown products formed by removing amino acids one by one from the N-terminal end; in rat serum the main enzymes are aminopeptidases and angiotensin-converting enzyme 2. Capping that end is the apparent reason for the modified version, but we found no published data showing it actually lasts longer or works better in a living animal. One cell study found that acetylating Semax's N-terminus changed how it binds copper and removed its ability to protect neuroblastoma (nerve-like) cells from copper toxicity, showing that the change can alter biology, not just stability 3. A 2005 rat study published in Russian found that changing or replacing the first amino acid of Semax could keep, weaken or abolish its effect on learning, depending on the change; acetylation and amidation were not among the changes tested 5.
What research shows
- No peer-reviewed study of the N-acetyl + amidated form was found in PubMed or Europe PMC (searched 2026-10-30). No registered human trials 9.
- Cell and chemistry study of N-acetyl Semax (not amidated), 2016: acetylation changed copper(II) binding; unlike Semax, acetylated Semax did not protect SH-SY5Y neuroblastoma cells from copper-induced toxicity. Zinc entry into cells was unaffected 3.
- Short 2013 Russian Academy report titled 'Stability of Semax acetyl to proteolysis in various biological media' 4; no abstract is available and we could not read the full text, so its findings are not reported here.
- For context, FDA's 2026 review of plain Semax found the clinical evidence insufficient for cerebral ischemia, migraine or trigeminal neuralgia, and noted many supporting studies are in Russian 2.
Doses studied in people
No published human (or animal) dosing data exist for N-acetyl Semax amidate; doses circulating online are not based on any study of this compound.
Read this first: these are the amounts given to participants in published studies or written on official prescribing labels, reported for reference. They are not recommendations. Trial doses were chosen for specific patients under medical supervision, and a dose that is safe in one person can be harmful in another.
Vial math
Many research vials hold 5 or 10 mg of powder. This table shows how much ends up in each mark on a U-100 insulin syringe for common amounts of added liquid. It is arithmetic only, not a dose.
| Vial | Liquid added | Concentration | Per unit (0.01 mL) | |
|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 50 mcg | Open in calculator |
| 5 mg | 2 mL | 2.5 mg/mL | 25 mcg | Open in calculator |
| 5 mg | 3 mL | 1.67 mg/mL | 16.7 mcg | Open in calculator |
| 10 mg | 1 mL | 10 mg/mL | 100 mcg | Open in calculator |
| 10 mg | 2 mL | 5 mg/mL | 50 mcg | Open in calculator |
| 10 mg | 3 mL | 3.33 mg/mL | 33.3 mcg | Open in calculator |
More sizes: all vial sizes · How this works: Syringes and units · Reconstitution guide.
Safety
- Unknown: no human or animal safety data on this form have been published.
- FDA found insufficient clinical information to describe even plain Semax's safety, could not find any human pharmacokinetic studies, and raised concern about immune reactions from impurities or aggregates in injected or nasal peptide products 2.
- FDA has noted that different salts and derivatives with different active ingredients are sold under the same 'Semax' name, which can put patients at risk 7.
- Products sold online are unregulated; identity, purity and dose are not verified by any regulator.
Report side effects of any drug or product to the FDA through MedWatch. For a possible poisoning in the US, call Poison Control at 1-800-222-1222.
Legal status
- FDA
- Not FDA-approved. No registered human trials found on ClinicalTrials.gov 9.
- Compounding
- N-acetyl Semax amidate is not named on FDA's compounding safety-risk page 6. FDA's July 2026 advisory-committee review covered only Semax free base and Semax acetate, and FDA's briefing document concluded the evidence weighs against adding those to the 503A bulks list 28. The modified form was not evaluated. HHS's October 28, 2026 interim enforcement-discretion policy for 503A compounding applies only to the peptide forms listed in its appendix, which for Semax is Semax free base for nasal use; N-acetyl Semax amidate, a different molecule, is not among the listed substances 111213.
- Sports (WADA)
- Not named on the WADA 2026 list. Semax has a Russian registration, but this modified form has no approval anywhere, so it appears to fall under S0 (non-approved substances), banned at all times 102. This is our reading; check with your anti-doping body.
- Other
- Not approved in any country that we found, including Russia, where only plain Semax is registered 2.
Rules change often. See Legal status of peptides for how these categories work.
History
Semax was developed in Russia and is registered there as 0.1% and 1% nasal drops 2. Russian chemists published a short 2013 report on the stability of acetylated Semax in biological fluids 4, and an Italian group studied N-acetyl Semax's metal-binding in 2016 3. The doubly modified N-acetyl/amidated form appears in PubChem as a catalog chemical 1, but we found no peer-reviewed study of it.
Common questions
Is N-Acetyl Semax Amidate the same as Semax?
Is there research on N-Acetyl Semax Amidate?
Is it stronger or longer-lasting than Semax?
Is it approved anywhere?
Is it banned in sport?
It is not named on WADA's 2026 list, but as an unapproved substance it appears to fall under the S0 class, banned at all times 10.
Related compounds
Semax
ACTH(4-7)-Pro-Gly-Pro · Met-Glu-His-Phe-Pro-Gly-Pro
Semax is a lab-made peptide built from a small piece of the stress hormone ACTH, with three amino acids added so it lasts longer.
Adamax
Adamantyl Semax (seller description)
Adamax is a lab-made peptide sold online as a 'stronger' version of Semax, a Russian nasal nootropic.
Selank
TP-7 · selank acetate
Selank is a short lab-made peptide developed in Russia as an anti-anxiety medicine.
Cerebrolysin
Porcine brain-derived peptide preparation
Cerebrolysin is an injectable medicine made from pig brain proteins that have been broken down into small peptides and free amino acids.
Sources
- PubChem: N-acetyl semax amidate (CID 172638603) Regulatory
- FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026: Semax-related bulk drug substances Regulatory
- Magrì A et al. Influence of the N-terminus acetylation of Semax on copper(II) and zinc(II) coordination and biological properties. J Inorg Biochem 2016 (PMID 27586814) Journal
- Shevchenko KV et al. Stability of Semax acetyl to proteolysis in various biological media. Dokl Biol Sci 2013 (PMID 23652441; Russian Academy journal, no abstract) Journal
- Glazova NIu et al. Effect of modification of the N-terminal region on the nootropic effect of Semax analogues. Izv Akad Nauk Ser Biol 2005 (PMID 16212268; in Russian) Journal
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 04/22/2026) Regulatory
- FDA presentations, Pharmacy Compounding Advisory Committee, July 24, 2026 (Semax nomenclature slide) Regulatory
- FDA: July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (meeting page) Regulatory
- ClinicalTrials.gov search: intervention 'N-acetyl semax' / 'semax' (no studies found, checked 2026-10-30) ClinicalTrials.gov
- WADA 2026 Prohibited List (full text, Asia Rugby copy), section S0 Non-approved substances Regulatory
- Federal Register (public inspection): HHS notice, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (filed Oct 28, 2026) Regulatory
- AJMC: HHS Draft Policy Eases Enforcement on 6 Compounded Peptides (Oct 2026) Regulatory
- FDA Law Blog (Hyman, Phelps & McNamara): The PEPTIDE-L Wave Reaches HHS: Enforcement Discretion ... Not the Finish Line (Oct 2026) Regulatory
Wondering how to judge the claims made about compounds like this one? The Academy track Thinking clearly about peptide claims walks through it. You can try the Academy free first.
Last reviewed 2026-10-30 · How we research · Found an error? See our corrections policy.